drugset / Trial / NCT03316638
A Study of a New Investigational Medicinal Product to Treat Patients with Advanced or Metastatic Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
W0101 combines a cytotoxic compound to a monoclonal antibody targeting a receptor commonly overexpressed in many cancers. The development of antibody-drug conjugates takes advantage of the specificity of the mAb while augmenting its ability to produce a cytotoxic effect. The expected benefits of antibody-drug conjugation are enhancement of cytotoxicity in target cells and limiting toxicities of cytotoxic drugs in normal tissues.
Timeline
- Start
- 2017-11-24
- Primary completion
- 2021-10-30
- Completion
- 2022-07-05
Outcome
Outcome not reported
Stopped (Enrollment): “delay in participants recruitment in cohort A3 and IMP manufacturing issues”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | W0101 | Unknown | — | Intravenous |
Indications
No indication recorded.